AAAS recently highlighted work conducted as part of a longstanding collaboration between NCL, the University of North Carolina-Charlotte and Ball State University,...
Nanotechnology Characterization Lab
Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.
The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.
There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.
News & Updates
Nanobiotix, a former NCL collaborator and Assay Cascade awardee, recently announced positive results from a phase 2/3 study of NBTXR3 in soft tissue sarcoma.
- 1 of 4
- next ›
Meet Us @
The 11th Swiss Pharma Science Day takes place August 22, 2018 at the University of Bern. NCL’s Director, Dr.
The 256th ACS meeting will be held in Boston, MA, August 19-23, 2018. The theme for this year’s meeting is Nanoscience, Nanotechnology & Beyond. Dr.
The theme for this year’s CLINAM meeting is Targeted Delivery and Precision Medicine ‐ The Building Blocks to Personalized Medicine.
- 1 of 2
- next ›